GlassScriptPhysician profile
Kenneth Merck
NPI 1740898337
$1,971.87
in general payments reported to CMS, 2019-2025
24 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.98 · 2022: $350 · 2023: $1,110 · 2024: $82.28 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $269.59 | 2022-2025 | |
| Axsome Therapeutics, INC. | $246.39 | 2023-2025 | Sunosi |
| Ani Pharmaceuticals, INC. | $184.26 | 2022-2023 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $181.49 | 2022-2023 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $172.48 | 2022-2023 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $115.09 | 2023-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.89 | 2022-2023 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $92.24 | 2022-2023 | Glassia |
| Astrazeneca Pharmaceuticals LP | $78.83 | 2022-2023 | Breztri, Fasenra |
| Regeneron Healthcare Solutions, INC. | $71.77 | 2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $67.31 | 2023 | Acthar |
| Glaxosmithkline, LLC. | $62.92 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Genzyme Corporation | $59.36 | 2023 | |
| Genentech USA, INC. | $51.82 | 2022-2023 | Esbriet, Xolair |
| Harmony Biosciences LLC | $36.41 | 2022-2023 | Wakix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.49 | 2023 | Tezspire |
| Idorsia Pharmaceuticals US INC | $26.53 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $21.71 | 2023 | |
| Mylan Specialty L.P. | $20.10 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.94 | 2022 | |
| Edwards Lifesciences Corporation | $18.99 | 2023 | Hemosphere |
| Resmed Corp | $13.76 | 2025 | |
| Boston Scientific Corporation | $12.98 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.52 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Merck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.